Espacenet search results on 03-02-2014 12:38

15 documents cited in relation to WO2011110838 (A2)
Displaying selected publications

Publication	Title	Page
WO2008045344 (A2)	METHODS TO DETERMINE RESPONSIVENESS T...	2
WO03077900 (A1)	A UNIFYING MECHANISM AND METHODS TO P...	3
WO9729759 (A1)	PHARMACEUTICAL COMPOSITION ENABLING T...	4
US4331648 (A)	N-Acetyl-cysteine protects against ca...	5
WO2010015590 (A1)	ORGANOTIN(IV) COMPLEXES WITH N-ACETYL...	6
WO2010039679 (A1)	COMPOSITIONS FOR PROLIFERATION OF CEL...	7
WO2011090741 (A2)	TREATMENT OF TUMOR PROTEIN 63 (p63) R...	8
JPH0840888 (A)	ANTITUMOR AGENT AGAINST MYELOMA-BASED...	9
XP022344808	p63 - Key molecule in the early phase...	10
XP002665835	Anticancer agent against myeloma type...	11
XP002665836	p63 siRNA (h): sc-36161	12
XP002665837	Loss of Delta Np63 alpha Promotes Inv...	13
XP022561631	p63 contributes to cell invasion and ...	14
WO2007037782 (A2)	METHOD FOR TREATING PROSTATE CONDITIONS	15
US5978740 (A)	Molecules comprising a calcineurin-li...	16

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2008 (17.04.2008)

PCT

(10) International Publication Number
WO 2008/045344 A2

(51) International Patent Classification:
G01N 33/50 (2006.01)

(21) International Application Number:
PCT/US2007/021433

(22) International Filing Date: 5 October 2007 (05.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/850,136 6 October 2006 (06.10.2006) US

(71) Applicant *(for all designated States except US)*: **THE GENERAL HOSPITAL CORPORATION** [US/US]; 55 Fruit Street, Boston, MA 02114 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ELLISEN, Leif, W.** [US/US]; 28 Marlboro Street, Newton, MA 02458 (US). **LEONG, Chee-Onn** [MY/US]; 63 Mt. Vernon Street, Boston, MA 02108 (US).

(74) Agents: **RESNICK, David, S.** et al.; Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110-2131 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *without international search report and to be republished upon receipt of that report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** METHODS TO DETERMINE RESPONSIVENESS TO CISPLATIN TREATMENT



(57) **Abstract:** The present invention relates, generally, to methods to identity subjects responsive to p73/p63 targeting agents such as platinum-based chemotherapy agents such as, but not limited to, cisplatin and cisplatin derivatives and analogues thereof. More particularly, the present invention relates to methods to identify a cancer responsive to a p73/p63 targeting treatment, such as chemotherapeutic agents such as cisplatin, by determining if the cancer expresses and/or has the activity of p63 isoforms such as DNp63 isoforms, and expresses and/or has the activity of p73 isoforms such as TAp73 or DNp73 isoforms. The present invention also relates to methods to identify a cancer unresponsive to a p73/p63 targeting treatment, such as chemotherapeutic agents such as cisplatin by determining if the cancer lacks the expression and/or activity of p63 isoforms such as DNp63 isoforms. The invention further provides kits to determine the expression and/or activity of p63 isoforms such as DNp63 isoforms, and/or the expression and/or activity of p73 isoforms such as TAp73 and/or DNp73 isoforms in a biological sample.

WO 2008/045344 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/077900 A1

(51) International Patent Classification[7]: A61K 31/195, 31/40

(21) International Application Number: PCT/US03/07686

(22) International Filing Date: 12 March 2003 (12.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/364,544 14 March 2002 (14.03.2002) US

(71) Applicant *(for all designated States except US)*: **PREVENTION, L.L.C.** [US/US]; 22635 Wilson Avenue, Waterloo, NE 68069 (US).

(71) Applicants and
(72) Inventors: **CAVALIERI, Ercole, L.** [US/US]; 22635 Wilson Avenue, Waterloo, NE 68069 (US). **ROGAN, Eleanor** [US/US]; 8210 Bowie Drive, Omaha, NE 68114 (US).

(74) Agents: **STEFFEY, Charles, E.** et al.; P.O. Box 2938, Minneapolis, MN 55402 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) Title: A UNIFYING MECHANISM AND METHODS TO PREVENT CANCER AND NEURODEGENERATIVE DISEASES



(57) Abstract: The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates.

WO 03/077900 A1

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/71 // (A61K 31/71, 31:195)

A1

(11) International Publication Number: **WO 97/29759**

(43) International Publication Date: 21 August 1997 (21.08.97)

(21) International Application Number: PCT/EP97/00627

(22) International Filing Date: 12 February 1997 (12.02.97)

(30) Priority Data:
MI96A000277 14 February 1996 (14.02.96) IT

(71) Applicant *(for all designated States except US)*: ZAMBON GROUP S.P.A. [IT/IT]; Via della Chimica, 9, I-36100 Vicenza (IT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DE FLORA, Silvio [IT/IT]; Via Ghirardelli Pescetto, 15, I-16167 Genova Nervi (IT). ALBINI, Adriana [IT/IT]; Salita della Provvidenza, 14/1b, I-16134 Genova (IT).

(81) Designated States: BR, CA, JP, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL COMPOSITION ENABLING TO INHIBIT CANCER METASTASIS FORMATION CONTAINING N-ACETYL-CYSTEINE AND DOXORUBICIN

(57) Abstract

The therapeutic association of N-acetyl-cysteine with Doxorubicin shows a remarkable synergic effect in inhibiting cancer metastasis formation. Pharmaceutical compositions containing the association and kit suitable for the administration of the two drugs are described.

United States Patent [19]

Myers, Jr. et al.

[11] **4,331,648**

[45] **May 25, 1982**

[54] **N-ACETYL-CYSTEINE PROTECTS AGAINST CARDIAC DAMAGE FROM SUBSEQUENTLY-ADMINISTERED CARDIO-TOXIC ANTHRA-CYCLINE IN CANCER THERAPY**

[75] Inventors: **Charles E. Myers, Jr.**, Rockville, Md.; **James H. Doroshow**, Upland, Calif.; **Gershon Y. Locker**, Chicago, Ill.

[73] Assignee: **The United States of America as represented by the Secretary of the Department of Health and Human Services**, Washington, D.C.

[21] Appl. No.: **190,064**

[22] Filed: **Sep. 23, 1980**

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 100,496, Dec. 5, 1979, abandoned, which is a continuation of Ser. No. 24,246, Mar. 27, 1979, abandoned.

[51] **Int. Cl.**[3] **A61K 31/70**; A61K 31/71

[52] **U.S. Cl.** **424/10**; 424/180; 424/181

[58] **Field of Search** 424/10

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,267,163 5/1981 DeFelice 424/180

OTHER PUBLICATIONS

Chemical Abstracts, 79: 142981a, (1973).
Chemical Abstracts, 92: 52213r, (1980).

Primary Examiner—Jerome D. Goldberg
Attorney, Agent, or Firm—Holman & Stern

[57] **ABSTRACT**

The cardiac damage, occurring after treatment with an anthracycline, such as adriamycin, is prevented when N-acetyl-cysteine is orally administered about one hour prior to the treatment with the anthracycline.

10 Claims, No Drawings

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 February 2010 (11.02.2010)

PCT

(10) International Publication Number
WO 2010/015590 A1

(51) **International Patent Classification**:
A61K 31/32 (2006.01) *A61P 35/00* (2006.01)
C07F 7/22 (2006.01)

(21) **International Application Number**:
PCT/EP2009/060006

(22) **International Filing Date**:
3 August 2009 (03.08.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
RM2008A000426 4 August 2008 (04.08.2008) IT

(71) **Applicant** *(for all designated States except US)*: **UNIVERSITA' DEGLI STUDI DI PALERMO** [IT/IT]; Piazza Marina 61, I-90133 Palermo (IT).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **PELLERITO, Claudia** [IT/IT]; c/o Dipartimento Chimica Inorganica, e Analitica "S. Cannizzaro", Viale delle Scienze - Ed 17, I-90128 Palermo (IT). **PRINZIVALLI, Cristina** [IT/IT]; c/o Dipartimento Chimica Inorganica, e Analitica "S. Cannizzaro", Viale delle Scienze - Ed 17, I-90128 Palermo (IT). **PELLERITO, Ornella** [IT/IT]; c/o Dipartimento Scienze Biochimiche, "Paolo Giaccone", Viale del Vespro 129, I-90127 Palermo (IT). **GIULIANO, Michela** [IT/IT]; c/o Dipartimento Scienze Biochimiche, "Paolo Giaccone", Viale del Vespro 129, I-90127 Palermo (IT).

(74) **Agents**: **GERVASI, Gemma** et al.; Notarbartolo & Gervasi S.p.a., Corso di Porta Vittoria 9, I-20122 Milan (IT).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title**: ORGANOTIN(IV) COMPLEXES WITH N-ACETYLCYSTEINE POSSESSING ANTITUMORAL ACTIVITY, PROCESS FOR THEIR PRODUCTION AND THEIR USE



(1)



(2)

(57) **Abstract**: Organotin(IV) compounds with N-acetylcysteine having the general formula (1) o (2): wherein: R_1, R_2 and R_3 are each independently selected from the group consisting of : H, an alkyl, alkoxyl, alkenyl or alkynyl group with up to 12 carbon atoms, an isocyclic or heterocyclic aromatic or aralkyl group with up to 12 carbon atoms, and they are preferably chosen from methyl, ethyl, butyl or phenyl, are synthetized by simple procedures from commercial products, and are active as anticancer agents. In particular, the Bu_2Sn-N-acetylcysteinate derivative was found to have a potent and selective anticancer activity in vitro against several cancer cell lines.

WO 2010/015590 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 April 2010 (08.04.2010)

PCT

(10) International Publication Number
WO 2010/039679 A1

(51) International Patent Classification:
C12N 5/071 (2010.01)

(21) International Application Number:
PCT/US2009/058723

(22) International Filing Date:
29 September 2009 (29.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/101,443 30 September 2008 (30.09.2008) US

(71) Applicant *(for all designated States except US)*: **THE HOSPITAL FOR SICK CHILDREN** [CA/CA]; 555 University Avenue, Toronto, Ontario, M5G 1X8 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MILLER, Freda** [CA/CA]; 87 Marlborough Avenue, Toronto, Ontario, M5R 1X5 (CA). **KAPLAN, David** [US/CA]; 87 Marlborough Avenue, Toronto, Ontario, M5R 1X5 (CA). **SMITH, Kristen** [US/US]; 138 W Marquita, San Clemente, CA 92675 (US). **PARIS, Maryline** [FR/CA]; 276 Silver Birch Avenue, Toronto, Ontario, M4E 3L5 (CA).

(74) Agent: **BELLIVEAU, Michael, J.**; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS

(57) **Abstract**: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.

WO 2010/039679 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 July 2011 (28.07.2011)

PCT

(10) International Publication Number
WO 2011/090741 A2

(51) **International Patent Classification**:
C12N 15/113 (2010.01) *A61K 31/7088* (2006.01)
A61K 48/00 (2006.01) *A61P 17/00* (2006.01)

(21) **International Application Number**:
PCT/US2010/062326

(22) **International Filing Date**:
29 December 2010 (29.12.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/290,540 29 December 2009 (29.12.2009) US

(71) **Applicant** *(for all designated States except US)*: **OPKO CuRNA, LLC** [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **COLLARD, Joseph** [US/US]; 1004, Brooks Lane, Delray Beach, Florida 33483 (US). **KHORKOVA SHERMAN, Olga** [US/US]; 18288 SE, Heritage Drive, Tequesta, Florida 33469 (US).

(74) **Agent**: **BROWDER, Monte, R.**; Opko Curna, LLC, 4400 Biscayne Boulevard, Miami, FL 33137 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) **Title**: TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63

FIGURE 1



(57) **Abstract**: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Protein 63 (p63), in particular, by targeting natural antisense polynucleotides of Tumor Protein 63 (p63). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of p63.

WO 2011/090741 A2

(19)日本国特許庁（ＪＰ）　(12) **公開特許公報**（Ａ）　(11)特許出願公開番号

特開平8－40888

(43)公開日　平成８年(1996)２月13日

(51)Int.Cl.[6]	識別記号	庁内整理番号	ＦＩ	技術表示箇所
Ａ６１Ｋ　31/195	ＡＤＵ	9455－4C		
Ｃ０７Ｃ 323/58		7419－4H		

審査請求　未請求　請求項の数１　ＯＬ　（全　４　頁）

(21)出願番号　特願平6－176879

(22)出願日　平成６年(1994)７月28日

(71)出願人　000000066
味の素株式会社
東京都中央区京橋１丁目15番１号
(72)発明者　小野崎菊夫
岐阜県可児市皐ケ丘９－128
(74)代理人　弁理士　川口　義雄　（外２名）

(54)【発明の名称】　ミエローマ系腫瘍抗癌剤

(57)【要約】
【目的】　ミエローマ系腫瘍抗癌剤を開発し、提供すること。
【構成】　有効成分としてＮ－アセチル－Ｌ－システインを含有することを特徴とするミエローマ系腫瘍抗癌剤

Document is not available for XP022344808

Document is not available for XP002665835

Document is not available for XP002665836

Document is not available for XP002665837

Document is not available for XP022561631

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 April 2007 (05.04.2007)

PCT

(10) International Publication Number
WO 2007/037782 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 31/56* (2006.01)
A61K 36/889 (2006.01) *A61K 31/4745* (2006.01)
A61K 31/496 (2006.01) *A61K 31/137* (2006.01)

(21) International Application Number:
PCT/US2006/004523

(22) International Filing Date: 8 February 2006 (08.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/651,101 8 February 2005 (08.02.2005) US

(71) Applicant *(for all designated States except US)*: **THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; OFFICE OF TECHNOGOLY DEVELOPMENT, Cb4105, 308 Bynum Hill, Chapel Hill, North Carolina 27599-4105 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SMITH, Gary** [US/US]; 95 Tillinghast Place, Buffalo, New York 14216 (US). **HUSS, Wendy** [US/US]; 133 School Street, Kenmore, New York 14217 (US).

(74) Agents: **LOPINSKI, John** et al.; HODGSON RUSS LLP, SUITE 2000, One M & t Plaza, Buffalo, New York 14203-2391 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2007/037782 A2

(54) Title: METHOD FOR TREATING PROSTATE CONDITIONS

(57) Abstract: The invention provides a method for inhibiting the aberrant growth of cells in a prostate tissue in an individual comprising administering to the individual an amount of an irihibitor of the Breast Cancer Resistance Protein (BCRP/ABCG2), where the amount of the BCRP inhibitor is effective to inhibit the growth of the aberrantly growing cells. The method is also useful for treating prostate tumors or benign prostatic hyperplasia/hypertrophy (BPH). Also disclosed is the phenotype for prostate stem cells as determined by immunohistochecmical localization methods. The prostate stem cells are positive for BCRP protein, negative for androgen receptor protein, negative for p63 protein, and negative for synaptophysin.

US005978740A

United States Patent [19]

Armistead et al.

[11] **Patent Number: 5,978,740**

[45] **Date of Patent: Nov. 2, 1999**

[54] **MOLECULES COMPRISING A CALCINEURIN-LIKE BINDING POCKET AND ENCODED DATA STORAGE MEDIUM CAPABLE OF GRAPHICALLY DISPLAYING THEM**

[75] Inventors: **David M. Armistead**, Maynard; **Matthew James Fitzgibbon**, Millis; **Mark Andrew Fleming**, Cambridge; **James P. Griffith**, Weston; **Eunice E. Kim**, Framingham; **Joseph L. Kim**, Natick; **Michael D. Sintchak**, Winchester; **John Allan Thomson**, Belmont; **Keith P. Wilson**, Hopkinton, all of Mass.

[73] Assignee: **Vertex Pharmaceuticals Incorporated**, Cambridge, Mass.

[21] Appl. No.: **08/512,815**

[22] Filed: **Aug. 9, 1995**

[51] **Int. Cl.**[6] **G06F 19/00**

[52] **U.S. Cl.** **702/19**; 702/27

[58] **Field of Search** 364/496–499, 364/578; 702/19, 27

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,833,233	5/1989	Carter	530/363
5,025,388	6/1991	Cramer, III et al.	364/496
5,331,573	7/1994	Balaji et al.	364/496
5,353,236	10/1994	Subbiah	364/499

FOREIGN PATENT DOCUMENTS

PCT/WO94/25860	11/1994	WIPO .

OTHER PUBLICATIONS

Barford, D. and Keller, J.C., "Co–crystallization of the Catalytic Subunit of the Serine/Threonine Specific Protien Phosphatase 1 from Human in Complex with Microcystin LR", *J. Mol. Biol.,* 235, pp. 763–766 (1994).

Griffith, J.P. et al., "X–Ray Structure of Calcineurin Inhibited by the Immunophilin–Immunosuppressant FKBP12–FK506 Complex", *Cell,* 82, pp. 507–522 Aug. 1995.

Guerini, D. and Klee, C.B., "Cloning of Human Calcineurin A: Evidence for Two Isozymes and Identification of a Polyproline Structural Domain", *Proc. Natl. Acad. Sci. USA,* 86, pp. 9183–9187 (1989).

Hubbard, M.J. and Klee, C.B., "Functional Domain Structure of Calcineurin A: Mapping by Limited Proteolysis", *Biochemistry,* 28, pp. 1868–1874 (1989).

Kissinger, C.R. et al., "Crystal Structures of Human Calcineurin and the Human FKBP12–FK506–Calcineurin Complex", *Nature,* 378, pp. 641–644 Dec. 1995.

Sträter, N. et al., "Crystal Structure of a Purple Acid Phosphatase Containing a Dinuclear Fe(III)–Zn(II) Active Site", *Science,* 268, pp. 1489–1492 Jun. 1995.

Villafranca, J.E. et al., "Protein Serine/Threonine Phosphatases", *Current Opinion in Biotech.,* 7, pp. 387–402 (1996) No month.

Andrus, M.B. and Schreiber, S.L., "Structure–Based Design of an Acyclic Ligand That Bridges FKBP12 and Calcineurin" *J. Am. Chem. Soc.,* 115, pp. 10420–10421 (1993).

Bierer, B.E. et al., "Cyclosporin A and FK506: Molecular Mechanisms of Immunosuppression and Probes for Transplantation Biology" *Curr. Opinion in Immunology,* 5, pp. 763–773 (1993).

Caffrey, M.V. et al. "Synthesis And Evaluation Of Dual Domain Macrocyclic FKBP12 Ligands" *Bioorg. Med. Chem. Lett.,* 4, pp. 2507–2510 (Nov., 1994).

Campbell, I.D. and Dwek, R.A., "Diffraction" in *Biological Spectroscopy,* The Benjamin/Cummings Publishing Company, Menlo Park, CA, pp. 299–326 (1984).

Holt, D.A. et al., "Design, Synthesis, and Kinetic Evaluation of High–Affinity FKBP Ligands and the X–ray Crystal Structures of Their Complexes with FKBP12" *J. Am. Chem. Soc.,* 115, pp. 9925–9938 (1993).

Kajihara, A. et al., "Protein Modelling Using a Chimera Reference Protein Derived From Exons" *Protein Engng,* 6, pp. 615–620 (1993).

Kunz, J. and Hall, M.N. "Cyclosporin A, FK506 and Rapamycin: More Than Just Immunosuppression" *TIBS,* 18, pp. 334–338.

Sharma, R.K. and Wang, J.H., "Calmodulin and Ca^{2+}–Dependent Phosphorylation and Dephosphorylation of 63–kDa Subunit–Containing Bovine Brain Calmodulin–Stimulated Cyclic Nucleotide Phosphodiesterase Isozyme" *J. Biol. Chem.,* 261, pp. 1322–1328 (1986).

Uhlin, U. et al., "Crystallization and Crystallographic Investigations of Ribonucleotide Reductase Protein R1 from *Escherichia coli*" *FEBS,* 336, pp. 148–152 (1993).

Wilson, K.P. et al. "Comparative X–ray Structures of the Major Binding Protein for the Immunosuppressant FK506 (Tacrolimus) in Unliganded Form and in Complex with FK506 and Rapamycin" *Acta Cryst.,* D51, pp. 511–521 (Jul., 1995).

Primary Examiner—James P. Trammell
Assistant Examiner—M. Kempo
Attorney, Agent, or Firm—Fish & Neave; James F. Haley, Jr.; N. Govindaswamy

[57] **ABSTRACT**

The present invention relates to crystallized molecules and molecular complexes which comprise the active site binding pocket or the FKBP12/FK506 binding pocket of calcineurin or close structural homologues to either binding pocket. This invention also relates to a data storage material encoded with the corresponding structure coordinates of those crystallized molecules or molecular complexes. Such data storage material is capable of displaying such molecules and molecular complexes as a graphical three-dimensional representation on a computer screen. In addition, this invention relates to methods of using the structure coordinates of those molecules or molecular complexes to solve the structure of homologous proteins. This invention also relates to methods of using the structure coordinates to screen and design compounds that bind to calcineurin or homologues thereof.

6 Claims, 109 Drawing Sheets